Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H30O5 |
Molecular Weight | 350.4492 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 5 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O
InChI
InChIKey=AOPOCGPBAIARAV-OTBJXLELSA-N
InChI=1S/C20H30O5/c1-2-17(21)11-8-5-9-14-18(22)12-6-3-4-7-13-19(23)15-10-16-20(24)25/h3-9,11-13,17-19,21-23H,2,10,14-16H2,1H3,(H,24,25)/b4-3+,9-5-,11-8+,12-6+,13-7-/t17-,18+,19-/m1/s1
Resolvin E1 (RvE1 or RX-10001) is a trihydroxy eicosapentaenoic acid metabolite that has a role as an anti-inflammatory agent and a human xenobiotic metabolite. This compound binds to leukotriene B4 (BLT-1) on neutrophils and to ERV-1/ChemR23 on monocyte/macrophages. Resolvin E1 has been shown to reverse experimental periodontitis and dysbiosis in rats. Furthermore, in a murine model of Alzheimer’s disease, Resolvin E1 (in combination with lipoxin A4) decreased neuroinflammation. Resolvin E1 was also suggested as a potential therapeutic target for psoriasis. A phase I clinical trial to test drug safety in healthy volunteers has been completed in 2009.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. | 2005 Mar 7 |
|
Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. | 2007 Mar 15 |
|
Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. | 2010 May |
|
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. | 2010 Oct |
|
Resolvins: natural agonists for resolution of pulmonary inflammation. | 2011 Jan |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
552830-51-0
Created by
admin on Sat Dec 16 02:17:41 GMT 2023 , Edited by admin on Sat Dec 16 02:17:41 GMT 2023
|
PRIMARY | |||
|
GND3JH08JA
Created by
admin on Sat Dec 16 02:17:41 GMT 2023 , Edited by admin on Sat Dec 16 02:17:41 GMT 2023
|
PRIMARY | |||
|
DB13105
Created by
admin on Sat Dec 16 02:17:41 GMT 2023 , Edited by admin on Sat Dec 16 02:17:41 GMT 2023
|
PRIMARY | |||
|
91000
Created by
admin on Sat Dec 16 02:17:41 GMT 2023 , Edited by admin on Sat Dec 16 02:17:41 GMT 2023
|
PRIMARY | |||
|
10473088
Created by
admin on Sat Dec 16 02:17:41 GMT 2023 , Edited by admin on Sat Dec 16 02:17:41 GMT 2023
|
PRIMARY | |||
|
81559
Created by
admin on Sat Dec 16 02:17:41 GMT 2023 , Edited by admin on Sat Dec 16 02:17:41 GMT 2023
|
PRIMARY |
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD